{ "id": "epvj0w558q", "slug": "epigenome-editing", "title": "Epigenome editing", "updated": "2026-10-15", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.biology", "label": "Biological foundations", "api_url": "https://www.edgepedia.org/api/v1/topics/life.biology" }, { "id": "life.biology.genetics", "label": "Genetics and genomic reference", "api_url": "https://www.edgepedia.org/api/v1/topics/life.biology.genetics" }, { "id": "life.biology.genetics.gene_editing_engineering", "label": "Genetic engineering, editing, and gene therapy", "api_url": "https://www.edgepedia.org/api/v1/topics/life.biology.genetics.gene_editing_engineering" } ], "geo": [ { "id": "geo.nongeo.t2001.life.biology.genetics.gene_editing_engineering", "label": "Non-geographic · 2001 to 2020: Genetic engineering, editing, and gene therapy", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.biology.genetics.gene_editing_engineering", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t2001", "label": "Non-geographic · 2001 to 2020", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001" }, { "id": "geo.nongeo.t2001.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life" }, { "id": "geo.nongeo.t2001.life.biology", "label": "Biological foundations", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.biology" }, { "id": "geo.nongeo.t2001.life.biology.genetics", "label": "Genetics and genomic reference", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.biology.genetics" }, { "id": "geo.nongeo.t2001.life.biology.genetics.gene_editing_engineering", "label": "Genetic engineering, editing, and gene therapy", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.biology.genetics.gene_editing_engineering" } ] } ], "excerpt": "Epigenome editing, also known as epigenetic editing or epigenome engineering, is a genome engineering method that alters gene expression without making DNA breaks, first demonstrated in 2002.", "snippet": "Epigenome editing, also known as epigenetic editing or epigenome engineering, is a genome engineering method that alters gene expression without making DNA breaks, first demonstrated in 2002.", "node": "life.biology.genetics.gene_editing_engineering", "markdown": "# Epigenome editing\n\nEpigenome editing is a set of genome engineering methods that add or remove epigenetic marks, such as [DNA methylation](https://www.edgepedia.org/dna-methylation) and histone modifications, at chosen genomic loci by fusing a chromatin-modifying effector to a programmable DNA-binding protein. Unlike nuclease, base, and prime editors, epigenome editors create no single- or double-strand DNA breaks; they modulate gene expression through DNA methylation, histone modifications, and chromatin conformation.[1](https://www.sciencedirect.com/science/article/abs/pii/S2468451126000188) The outcome can be a transient change or a precise, long-term epigenetic state that persists without continued expression of the editing machinery.[2](https://www.nature.com/articles/nmeth.3733) The approach was first demonstrated in 2002, when an engineered zinc-finger protein fused to a histone methyltransferase showed that H3K9 methylation is causative in gene repression.[3](https://doi.org/10.1016/s0960-9822%2802%2901391-x)\n\n| Property | Detail |\n|---|---|\n| DNA breaks | None; expression is changed via methylation and histone marks[1](https://www.sciencedirect.com/science/article/abs/pii/S2468451126000188) |\n| Typical expression change | 10–100-fold with first-generation KRAB or VP64 dCas systems[4](https://www.mdpi.com/1422-0067/26/13/6371) |\n| Durability in cells | CRISPRoff silencing maintained for more than 450 cell divisions[5](https://www.cell.com/cell/fulltext/S0092-8674%2821%2900353-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867421003536%3Fshowall%3Dtrue) |\n| Durability in vivo | EpiReg-T delivered via LNP (with a second intravenous injection on day 30) gave >90% PCSK9 silencing for 343 days in macaque liver[6](https://www.nature.com/articles/s41587-025-02838-y) |\n| Methylation footprint | ~35 bp window with dCas9-DNMT3A[7](https://academic.oup.com/nar/article-pdf/44/12/5615/17436386/gkw159.pdf) up to 4.5 kb with SunTag-directed DNMT3A[8](https://link.springer.com/article/10.1186/s13059-017-1306-z) |\n| Off-target methylation | On average 89 ± 11% of day-3 differentially methylated regions were shared between targeting and non-targeting gRNAs[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC12924462/) |\n| First demonstration | 2002, zinc finger fused to a histone methyltransferase[3](https://doi.org/10.1016/s0960-9822%2802%2901391-x) |\n\n## How it works\n\nThe most common targeting module is a catalytically inactivated Cas9 (dCas9) guided by a single-guide RNA. The dCas9–sgRNA complex requires a PAM of 3–6 nucleotides and forms an R-loop between an approximately 20-nucleotide RNA spacer and the target protospacer.[4](https://www.mdpi.com/1422-0067/26/13/6371) dCas9 alone represses transcription poorly in eukaryotes: steric blocking reduces mRNA roughly 300-fold in prokaryotes with one sgRNA and up to 1000-fold with two, but only about 2-fold in mammalian cells, which is why effector domains such as VP64, KRAB, and SID are needed.[10](https://www.mdpi.com/1422-0067/24/5/4778)\n\nEffectors write or erase marks that recruit endogenous regulatory machinery. DNMT3A with its cofactor DNMT3L catalyzes de novo CpG methylation, while the KRAB domain recruits KAP1/TRIM28 and heterochromatin-forming complexes, leading to H3K9 trimethylation.[11](https://link.springer.com/protocol/10.1007/978-1-0716-5547-4_5) DNMT3A multimerization drives methylation spreading: an R832E mutant that disrupts multimerization confines methylation to 10–50 bp from the binding site.[12](https://www.babraham.ac.uk/sites/default/files/media/files/27899645.pdf) On the activation side, the p300 histone acetyltransferase deposits H3K27 acetylation, and LSD1 removes H3K4me2 at putative enhancers, downregulating proximal genes.[13](https://link.springer.com/article/10.1186/s13072-015-0023-7)\n\n## How it is done\n\nA practitioner first selects an effector matching the goal (methylation, demethylation, acetylation, or KRAB repression), then designs guide RNAs; SpCas9-based tools target any 20 bp sequence followed by an NGG PAM.[7](https://academic.oup.com/nar/article-pdf/44/12/5615/17436386/gkw159.pdf) Foundational studies used plasmid-based transient transfection.[11](https://link.springer.com/protocol/10.1007/978-1-0716-5547-4_5) AAV packaging limits the expression cassette to under 4.7 kbp including promoters, which excludes large Cas systems.[10](https://www.mdpi.com/1422-0067/24/5/4778)\n\nValidation combines three assay classes: chromatin immunoprecipitation, bisulfite sequencing, and transcriptomic profiling, to confirm locus specificity and functional regulation.[11](https://link.springer.com/protocol/10.1007/978-1-0716-5547-4_5) Because no DNA breaks are made, off-target analysis relies on RNA-seq, ChIP-seq, and ATAC-seq rather than the break-based assays used for nucleases.[1](https://www.sciencedirect.com/science/article/abs/pii/S2468451126000188) With plasmid transfection, methylation activity peaks between days 5 and 15, and cultured cells lose the construct after about 10 days.[7](https://academic.oup.com/nar/article-pdf/44/12/5615/17436386/gkw159.pdf)\n\n## Origin\n\nZinc-finger proteins provided the first programmable DNA-binding domains for synthetic transcription factors in the 1990s.[4](https://www.mdpi.com/1422-0067/26/13/6371) In 2002, Andrew W. Snowden and colleagues targeted H3K9 methylation with a zinc-finger fusion in *Current Biology*, showing it sufficient to initiate repression.[3](https://doi.org/10.1016/s0960-9822%2802%2901391-x) In 2013, Morgan L. Maeder and colleagues reported TALE-TET1 fusions for targeted demethylation[14](https://doi.org/10.1038/nbt.2726) and Eric M. Mendenhall and colleagues reported TALE-histone demethylase fusions editing enhancer marks.[15](https://doi.org/10.1038/nbt.2701) Also in 2013, [Luke A. Gilbert](https://www.edgepedia.org/luke-a-gilbert) and colleagues attached effectors to dCas9 for RNA-guided repression and activation (CRISPRi/CRISPRa) in *Cell*.[16](https://doi.org/10.1016/j.cell.2013.06.044) Silvana Konermann and colleagues engineered CRISPR-SAM for genome-scale activation in 2014.[17](https://doi.org/10.1038/nature14136) In 2015, Isaac B. Hilton and colleagues described the first targetable epigenome editing protein with histone acetyltransferase activity (dCas9-p300)[2](https://www.nature.com/articles/nmeth.3733) and Pratiksha I. Thakore and colleagues silenced distal regulatory elements with dCas9-KRAB.[18](https://doi.org/10.1038/nmeth.3630) In 2016, Aleksandar Vojta and colleagues built the first CRISPR-Cas9-based targeted CpG methylation tool (dCas9-DNMT3A)[7](https://academic.oup.com/nar/article-pdf/44/12/5615/17436386/gkw159.pdf); X. Shawn Liu and colleagues reported dCas9-Tet1 and dCas9-Dnmt3a editing[19](https://doi.org/10.1016/j.cell.2016.08.056); Xingxing Xu and colleagues described dCas9-TET1 demethylation[20](https://doi.org/10.1038/celldisc.2016.9); Peter Stepper and colleagues added the chimeric dCas9–Dnmt3a–Dnmt3L methyltransferase[12](https://www.babraham.ac.uk/sites/default/files/media/files/27899645.pdf); Sumiyo Morita and colleagues achieved in vivo demethylation with dCas9–peptide repeat and scFv–TET1 fusions[21](https://doi.org/10.1038/nbt.3658); and Angelo Amabile and colleagues demonstrated inheritable silencing by hit-and-run editing.[22](https://doi.org/10.1016/j.cell.2016.09.006) Tyler S. Klann and colleagues reported the first complementary gain- and loss-of-function epigenome editing screens in 2017,[23](https://www.annualreviews.org/content/journals/10.1146/annurev-genom-083117-021632) Christian Pflueger and colleagues the modular SunTag-DNMT3A system in 2018,[24](https://doi.org/10.1101/gr.233049.117) and James K. Nuñez and colleagues CRISPRoff and CRISPRon in 2021.[5](https://www.cell.com/cell/fulltext/S0092-8674%2821%2900353-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867421003536%3Fshowall%3Dtrue)\n\n## Variants\n\n**CRISPRoff** is a single dCas9 fusion combining DNMT3A, DNMT3L, and a KRAB repressor, establishing both DNA methylation and repressive histone marks; **CRISPRon**, a dCas9-TET1 fusion separated by an 80 amino acid XTEN80 linker, reactivates CRISPRoff-silenced genes in more than 70% of cells.[5](https://www.cell.com/cell/fulltext/S0092-8674%2821%2900353-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867421003536%3Fshowall%3Dtrue) CRISPR-SAM and SunTag architectures recruit additional activator domains through aptamer-modified sgRNAs or repeating peptide arrays.[4](https://www.mdpi.com/1422-0067/26/13/6371) The modular dCas9-SunTag-DNMT3A system is tunable, more potent at target sites, and shows minimal off-target methylation compared with direct fusions.[24](https://doi.org/10.1101/gr.233049.117) The CHARM strategy recruits endogenous DNMT3A by attaching a DNA-binding protein to the DNMT3L domain and requires an H3 tail unmethylated at lysine 4 (H3K4me0) for DNMT3A activation;[4](https://www.mdpi.com/1422-0067/26/13/6371) the related CRISPRcharm replaces the bulky DNMT3A and KRAB effectors with a 12 amino acid H3K4me0 peptide.[1](https://www.sciencedirect.com/science/article/abs/pii/S2468451126000188) The methylation footprint depends on the architecture: dCas9-DNMT3A methylates a ~35 bp window heritable across mitotic divisions,[7](https://academic.oup.com/nar/article-pdf/44/12/5615/17436386/gkw159.pdf) dCas9-Dnmt3a-Dnmt3L covers entire CpG islands up to 1000 bp from the target,[12](https://www.babraham.ac.uk/sites/default/files/media/files/27899645.pdf) and a single guide RNA with dCas9-SunTag-DNMT3A methylated a 4.5-kb window, repressing HOXA5 by 80%.[8](https://link.springer.com/article/10.1186/s13059-017-1306-z) In a head-to-head benchmark, dCas9-3A3A and dCas9-3A3L gave the strongest on-target methylation (average \\( \\beta \\approx 68\\% \\)), versus about 40% for CRISPRoff, dCas9-SunTag, and dCas9-3A, and about 26% for dCas9-M.SssI and dCas9-3A-KRAB; CRISPRoff was the most effective at depositing and maintaining on-target methylation over 30 days, attributed to its KRAB domain recruiting KAP1, HP1, HDACs, and histone methyltransferases.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC12924462/)\n\n## Applications\n\nHigh-throughput screens with complementary gain- and loss-of-function editors annotate functional regulatory elements in the noncoding genome.[23](https://www.annualreviews.org/content/journals/10.1146/annurev-genom-083117-021632) Disease-model examples include dCas9-DNMT3A methylation of the APP promoter, which reduced amyloid-β production and improved neuronal survival; BCL11A enhancer repression to induce fetal gamma-globin for sickle cell disease and beta-thalassemia; dCas9-TET1 reactivation of hypermethylated tumor suppressor genes; and EpiCRISPR repression of Arx in pancreatic α-cells, initiating partial reprogramming toward an insulin-producing phenotype.[11](https://link.springer.com/protocol/10.1007/978-1-0716-5547-4_5) Durability varies by design: transient CRISPRoff expression writes silencing maintained for more than 450 cell divisions,[5](https://www.cell.com/cell/fulltext/S0092-8674%2821%2900353-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867421003536%3Fshowall%3Dtrue) and EpiReg-T delivered via LNP, with a second intravenous injection on day 30, silenced PCSK9 in macaque liver for 343 days.[6](https://www.nature.com/articles/s41587-025-02838-y) Therapeutic programs are emerging: AAV-delivered CHARM shut off the prion gene throughout the mouse brain, with a single injection eliminating over 80% of prion protein against the roughly 20% needed to improve symptoms,[25](https://pmc.ncbi.nlm.nih.gov/articles/PMC12925790/) and Frederic Tremblay and colleagues reported a potent epigenetic editor targeting human PCSK9 for durable LDL cholesterol reduction.[26](https://doi.org/10.1038/s41591-025-03508-x)\n\n## Limitations and alternatives\n\nPublished comparisons disagree on genome-wide off-target methylation by direct-fusion dCas9-DNMT3A: Vojta and colleagues detected no genome-wide change, with LINE-1 methylation unchanged,[7](https://academic.oup.com/nar/article-pdf/44/12/5615/17436386/gkw159.pdf) while Pflueger and colleagues found consistent genome-wide off-target deposition that limits functional interpretation.[24](https://doi.org/10.1101/gr.233049.117) Off-target methylation is largely guide-independent: on average 89 ± 11% of day-3 DMRs were shared between targeting and non-targeting gRNAs, subsiding by day 7.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC12924462/) H3K36me3 and H3K27ac chromatin marks correlate with resistance to short-term repression and long-term silencing, respectively,[27](https://pubmed.ncbi.nlm.nih.gov/35234927/) and editing in differentiated cells has a poorer, less sustainable effect than in stem cells because fixed chromatin requires ATP-dependent remodelers and multiple factors.[10](https://www.mdpi.com/1422-0067/24/5/4778)\n\nDelivery and immunogenicity constrain therapy: the complete AAV genome has a packaging capacity of approximately 4.7 kb including the two inverted terminal repeats, leaving limited payload for full expression cassettes built around full-length dCas9 (~4.2 kb) or TALE proteins (~3 kb per monomer), whereas zinc-finger arrays (~0.5–1 kb) allow compact fusions such as ZF-DNMT3A at 2.8 kb,[25](https://pmc.ncbi.nlm.nih.gov/articles/PMC12925790/) and pre-existing antibodies against *S. aureus* and *S. pyogenes* Cas9 are present in 78% and 58% of human donors.[25](https://pmc.ncbi.nlm.nih.gov/articles/PMC12925790/) Compared with CRISPRi/CRISPRa, dCas9-VP64 activation is often modest, and second-generation systems (VPR, SAM) achieve higher expression but are large and complex;[1](https://www.sciencedirect.com/science/article/abs/pii/S2468451126000188) unlike nuclease knockout, epigenome editing leaves the DNA sequence intact.[1](https://www.sciencedirect.com/science/article/abs/pii/S2468451126000188)\n\n## References\n\n1. [Clinical Translation of Epigenome Editing Technologies (Trends in Biotechnology, 2026)](https://www.sciencedirect.com/science/article/abs/pii/S2468451126000188)\n2. [Editing the epigenome: technologies for programmable transcription and epigenetic modulation | Nature Methods](https://www.nature.com/articles/nmeth.3733)\n3. [Gene-Specific Targeting of H3K9 Methylation Is Sufficient for Initiating Repression In Vivo (Current Biology, 2002)](https://doi.org/10.1016/s0960-9822%2802%2901391-x)\n4. [Epigenome Engineering Using dCas Systems for Biomedical Applications and Biotechnology: Current Achievements, Opportunities and Challenges (Int J Mol Sci, 2025)](https://www.mdpi.com/1422-0067/26/13/6371)\n5. [S0092 8674(21)00353 6 (cell.com)](https://www.cell.com/cell/fulltext/S0092-8674%2821%2900353-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867421003536%3Fshowall%3Dtrue)\n6. [Design of optimized epigenetic regulators for durable gene silencing with application to PCSK9 in nonhuman primates | Nature Biotechnology (2025)](https://www.nature.com/articles/s41587-025-02838-y)\n7. [Repurposing the CRISPR-Cas9 system for targeted DNA methylation (Vojta et al., Nucleic Acids Research 2016)](https://academic.oup.com/nar/article-pdf/44/12/5615/17436386/gkw159.pdf)\n8. [DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A (Huang et al., Genome Biology 2017)](https://link.springer.com/article/10.1186/s13059-017-1306-z)\n9. [Comprehensive profiling of CRISPR/dCas9 epigenome editors indicates a complex link between on and off target effects (Genome Biology)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12924462/)\n10. [Toward the Development of Epigenome Editing-Based Therapeutics: Potentials and Challenges (Int J Mol Sci, 2023)](https://www.mdpi.com/1422-0067/24/5/4778)\n11. [An Overview of Programmable Epigenetic Editing Based on CRISPR Tools for Gene Expression Regulation (Springer protocol chapter)](https://link.springer.com/protocol/10.1007/978-1-0716-5547-4_5)\n12. [Efficient targeted DNA methylation with chimeric dCas9–Dnmt3a–Dnmt3L methyltransferase (Stepper et al., Nucleic Acids Research)](https://www.babraham.ac.uk/sites/default/files/media/files/27899645.pdf)\n13. [Strategies for precision modulation of gene expression by epigenome editing: an overview | Epigenetics & Chromatin](https://link.springer.com/article/10.1186/s13072-015-0023-7)\n14. [Morgan L Maeder and colleagues (2013). Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nature Biotechnology.](https://doi.org/10.1038/nbt.2726)\n15. [Eric M Mendenhall and colleagues (2013). Locus-specific editing of histone modifications at endogenous enhancers. Nature Biotechnology.](https://doi.org/10.1038/nbt.2701)\n16. [Luke A. Gilbert and colleagues (2013). CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes. Cell.](https://doi.org/10.1016/j.cell.2013.06.044)\n17. [Silvana Konermann and colleagues (2014). Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature.](https://doi.org/10.1038/nature14136)\n18. [Pratiksha I Thakore and colleagues (2015). Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nature Methods.](https://doi.org/10.1038/nmeth.3630)\n19. [X. Shawn Liu and colleagues (2016). Editing DNA Methylation in the Mammalian Genome. Cell.](https://doi.org/10.1016/j.cell.2016.08.056)\n20. [Xingxing Xu and colleagues (2016). A CRISPR-based approach for targeted DNA demethylation. Cell Discovery.](https://doi.org/10.1038/celldisc.2016.9)\n21. [Sumiyo Morita and colleagues (2016). Targeted DNA demethylation in vivo using dCas9–peptide repeat and scFv–TET1 catalytic domain fusions. Nature Biotechnology.](https://doi.org/10.1038/nbt.3658)\n22. [Angelo Amabile and colleagues (2016). Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. Cell.](https://doi.org/10.1016/j.cell.2016.09.006)\n23. [Editing the Epigenome: Reshaping the Genomic Landscape | Annual Review of Genomics and Human Genetics](https://www.annualreviews.org/content/journals/10.1146/annurev-genom-083117-021632)\n24. [Christian Pflueger and colleagues (2018). A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs. Genome Research.](https://doi.org/10.1101/gr.233049.117)\n25. [Epigenome editing based treatment: Progresses and challenges (Molecular Therapy, PMC-hosted review)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12925790/)\n26. [Frederic Tremblay and colleagues (2025). A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels. Nature Medicine.](https://doi.org/10.1038/s41591-025-03508-x)\n27. [Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing (O'Geen et al., Nucleic Acids Research 2022)](https://pubmed.ncbi.nlm.nih.gov/35234927/)\n\n---\n*Topic: Encyclopedia › Life and health › Biological foundations › Genetics and genomic reference › Genetic engineering, editing, and gene therapy*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/epigenome-editing", "markdown_url": "https://www.edgepedia.org/epigenome-editing.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Epigenome editing\", Edgepedia (EdgeChat), https://www.edgepedia.org/epigenome-editing. Edgepedia Community License 1.0.", "credit_md": "\"[Epigenome editing](https://www.edgepedia.org/epigenome-editing)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/epigenome-editing](https://www.edgepedia.org/epigenome-editing). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Epigenome editing\", Edgepedia (EdgeChat), https://www.edgepedia.org/epigenome-editing. Edgepedia Community License 1.0.", "speakable": "Epigenome editing, also known as epigenetic editing or epigenome engineering, is a genome engineering method that alters gene expression without making DNA breaks, first demonstrated in 2002." }